<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Comparison of FDA-approved MHT with custom-compounded bioidentical HT</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Comparison of FDA-approved MHT with custom-compounded bioidentical HT</h1>
<div class="graphic"><div class="figure"><div class="ttl">Comparison of FDA-approved MHT with custom-compounded bioidentical HT</div><div class="cntnt"><table cellspacing="0"><colgroup width="20%"></colgroup><colgroup span="2" width="40%"></colgroup> <tbody> <tr class="border_bottom_thick"> <td class="subtitle1"> </td> <td class="subtitle1">MHT (FDA approved)</td> <td class="subtitle1">BIH (unregulated)</td> </tr> <tr class="divider_bottom"> <td><strong>Goal of intervention</strong></td> <td> <p>Treatment: Clinicians prescribe estrogen to treat symptoms (primarily vasomotor)</p> They add progestin only for females with a uterus to prevent endometrial hyperplasia</td> <td> <p>Replacement: Clinicians prescribe replacing multiple sex steroids with the goal of restoring levels to the premenopausal range</p> Progesterone is often recommended for all females, even those without a uterus</td> </tr> <tr class="divider_bottom"> <td><strong>Pretreatment testing</strong></td> <td> <p>No pretreatment testing is required</p> Baseline hormones do not predict dose requirements</td> <td>Extensive salivary or blood testing is required</td> </tr> <tr class="divider_bottom"> <td><strong>Biochemical testing for monitoring</strong></td> <td>This is rarely needed</td> <td>Routine salivary or blood testing to monitor and adjust doses is required</td> </tr> <tr class="divider_bottom"> <td><strong>FDA approval status and concerns</strong></td> <td>FDA-approved estrogens and progestins, including 17-beta estradiol and progesterone, are required to: <ol> <li>Demonstrate sufficient purity, potency, efficacy, and safety for approval</li> <li>Have a failure rate of &lt;2% in quality and potency tests</li> <li>Have indications (hot flashes, vaginal atrophy, prevention of bone loss)</li> <li>Be supported by well-conducted RCTs</li> <li>Have package inserts that provide extensive product information, which may include black box warnings</li> <li>Have all adverse events reported to the FDA both before approval and after marketing</li> <li>E3 not approved</li> </ol> </td> <td>Compounded bioidenticals have: <ol> <li>No requirement to prove efficacy or safety before use</li> <li>No requirement for routine monitoring for purity or potency (sporadic assessments indicate high failure rates)</li> <li>Unsupported claims that the approach is safer and more effective than conventional HT</li> <li>No requirement for package inserts or black box warnings</li> <li>No listed concerns about possible overdosing or underdosing or the risk of higher estrogen/inadequate progesterone exposure</li> <li>No requirement for adverse event reporting</li> <li>E3 is a commonly included agent</li> </ol> </td> </tr> <tr class="divider_bottom"> <td><strong>Timing and duration of treatment</strong></td> <td>Perimenopause, ages 50 to 59, or &lt;10 years after menopause is recommended</td> <td>There are no age or duration restrictions</td> </tr> <tr class="divider_bottom"> <td><strong>Evidence for efficacy (relief of symptoms)</strong></td> <td>There is 80 to 90% relief with appropriate estrogen doses</td> <td>There is anecdotal evidence for efficacy</td> </tr> <tr class="divider_bottom"> <td><strong>Other benefits</strong></td> <td> <p>Alleviating adverse mood</p> Reduction in fracture</td> <td> <p>Energy</p> <p>Vitality</p> Increased attractiveness (these are only claims and not supported by RCTs)</td> </tr> <tr> <td><strong>Risks</strong></td> <td> <ol class="numbers_to_nine"> <li>Breast cancer: E + P after five years of use</li> <li>CVD: Risk of CHD, stroke, particularly in older females (WHI), safer in younger menopausal females because of very low absolute risk (ages 50 to 59)</li> <li>VTE: Small excess at all ages, but absolute risk small in younger females ages 50 to 59</li> <li>Gallbladder disease</li> <li>Urinary incontinence</li> </ol> </td> <td>The lack of evidence for harm (due to overall lack of evidence of any sort) is suggested by some of these products as evidence of safety</td> </tr> </tbody></table></div><div class="graphic_footnotes">MHT: menopausal hormone therapy; FDA: US Food and Drug Administration; BIH: custom-compounded bioidentical hormone therapy; RCT: randomized controlled trial; E3: estriol; HT: hormone therapy; E + P: estrogen plus progestin; CVD: cardiovascular disease; CHD: coronary heart disease; WHI: Women's Health Initiative; VTE: venous thromboembolism.</div><div class="graphic_reference">Republished with permission of The Endocrine Society, from Santoro N, Braunstein GD, Butts CL, et al. Compounded bioidentical hormones in Endocrinology practice: An Endocrine Society Scientific Statement. J Clin Endocrinol Metab 2016; 101:1318. Copyright © 2016; permission conveyed through Copyright Clearance Center, Inc.</div><div id="graphicVersion">Graphic 107768 Version 3.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
